

Bill, living with transthyretin amyloidosis, and his wife, Maura



Corporate Update Call:
Launch of New Universal CAR-T Company
with Cellex and Blackstone Life Sciences
and Intellia *Ex Vivo* Pipeline Updates

June 22, 2021

Intellia Therapeutics' Legal Disclaimer

This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding: its strategy, business plans and focus; its ability to quickly and efficiently realize the scope and potential of its genome-editing technology; its ability to maintain, expand and maximize its intellectual property portfolio and pipeline as well as accelerate clinical validation for its platform; the therapeutic value and development potential of CRISPR/Cas-9 gene editing technologies and therapies; its ability to combine its allogeneic T cell platform and CRISPR-based cell engineering with GEMoaB’s universal CAR-T platform; the expected strategic benefits and value of the formation of the new company, resulting collaborations, and use of Cellex’s cell therapy manufacturing sites; its expectations on the new company’s ability to develop CAR-T Cell therapies for immunoncology and autoimmune diseases and the timing and potential success of such therapies; its ability to optimize the impact of its collaborations on its development programs, including but not limited to its collaboration with BXLS, Cellex, or the new company; the ability of BXLS, Cellex, Intellia, and the new company to obtain all regulatory approvals necessary to close the transaction; its and the new company’s ability to enter into a license and collaboration agreement and co-development and co-promotion agreement; Intellia’s ability to submit an IND or equivalent regulatory filing for NTLA-5001 in mid-2021; and Intellia’s ability to nominate its first allogeneic development candidate by the 1H 2022.

Any forward-looking statements in this presentation are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of Intellia’s licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for the new company’s product candidates; the risk that any one or more of the new company’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the risk that Intellia’s collaborations with BXLS, Cellex, or the new company or its other collaborations will not continue or will not be successful. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release represent Intellia’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Intellia explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

Intellia, Cellex and Blackstone Launch New Company to Develop Allogeneic Universal CAR-T Cell Therapies, With \$250M Committed Funding

Concurrent Cellex deal enables expansion and acceleration of Intellia's ex vivo pipeline with expanded manufacturing capabilities

Intellia's Key Goals

Realize significant value by combining CRISPR/Cas9 with Universal CAR-T (UniCAR, RevCAR) technologies

Strengthen Intellia's investment in core areas of strategic focus, including wholly owned allogeneic programs

New Company Combines Advanced CRISPR Engineering From Intellia With a Universal CAR-T Cell Construct from GEMoab



Leading genome editing capabilities with differentiated allogeneic platform




CRISPR/Cas9 Platform



Allogeneic Cell Engineering



Clinically-validated Universal UniCAR/RevCAR platform



Switchable CAR-T Platform

Modular Targeting Molecules



Parent company of GEMoab

Established CMO GMP Cell Therapy Manufacturing

Intellia Receives Significant Value From the New Venture with Blackstone and Cellex, as well as Concurrent Agreement with Cellex

- Rights to **2 Co/Co options** in U.S. and key European countries on allogeneic universal CAR-T products
 - Intellia leads U.S. commercialization
- **Additional validation** of Intellia's proprietary allogeneic platform
- Hold **substantial equity stake** in new company
- **Access to Cellex cell therapy manufacturing site and allogeneic cell donations** via a preferred relationship
 - Supports Intellia's wholly owned *ex vivo* pipeline
 - Expanded capacity to handle additional pipeline growth

Intellia's Proprietary Engineering Platform Provides Flexibility to Expand into Other Cell Therapies

CELL ENGINEERING PLATFORM

Highly efficient sequential editing

Optimal cell performance

Scalable manufacturing process

ENABLES VERSATILE SOLUTIONS BY “MIXING AND MATCHING”

Cell Type

HSCs, T cells
NK cells, Macrophages



Targeting Modality

TCRs
CAR-Ts, Universal CARs




Rewiring Instructions

Immune-enhancing edits
Novel targets



Intellia Retains Rights Across a Diverse *Ex Vivo* Landscape



Intellia Gains Access to Important GMP Manufacturing Services from Cellex Under a Preferred Customer Agreement



World-leading manufacturing...

- Manufacturing of **intermediates and final products** for CAR-T cell products
- **Fully automated, audited and inspected GMP facility** including Quality Management, Control and Systems
- **Experienced and large** collection centers for allogeneic cell donations based in Cologne and Dresden
- **Worldwide distribution** of cell products including Same-Day Delivery for US and Europe

...to support and accelerate key programs.



Preferred relationship and dedicated capacity to support Intellia's wholly owned engineered cell therapy programs



High quality and diverse **donor cells** to support allogeneic platform

Expanding and Accelerating Intellia's *Ex Vivo* Pipeline



PROGRAM	APPROACH	Research	IND-Enabling	Early-stage Clinical	Late-stage Clinical	PARTNER
<i>Ex Vivo</i>: CRISPR <u>creates</u> the therapy						
OTQ923 / HIX763: Sickle Cell Disease	HSC	[Progress bar: Research to Early-stage Clinical]				NOVARTIS Intellia ¹ THERAPEUTICS
NTLA-5001: Acute Myeloid Leukemia	WT1-TCR	[Progress bar: Research to IND-Enabling]				Intellia THERAPEUTICS
Solid Tumors	WT1-TCR	[Progress bar: Research]				Intellia THERAPEUTICS
Allo Undisclosed	Undisclosed	[Progress bar: Research]				Intellia THERAPEUTICS
Other Novartis Programs	CAR-T, HSC, OSC, Undisclosed	[Progress bar: Research]				NOVARTIS Intellia THERAPEUTICS

- ***Expect to submit an IND or equivalent regulatory filing for NTLA-5001 in mid-2021***
- ***Plan to nominate first allogeneic development candidate by the 1H 2022***

¹ Milestones & royalties **CAR-T**: Chimeric Antigen Receptor T cells **HSC**: Hematopoietic Stem Cells **OSC**: Ocular Stem Cells.



Q&A

Intellia Corporate Update Call

Intellia

THERAPEUTICS